Dr. Katarzyna Jerzak reviews SABCS 2025 results from HER2CLIMB-05, where tucatinib maintenance significantly improved progression-free survival in HER2-positive metastatic breast cancer, with benefit across hormone-receptor subgroups and a well-tolerated safety profile.
